^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
huCART19-IL18
i
Other names: huCART19-IL18
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
University of Pennsylvania
Drug class:
CD19-targeted CAR-T immunotherapy, IL-18 stimulant
Related drugs:
25d
UPCC15420: huCART19-IL18 in CD19+ Cancers (clinicaltrials.gov)
P1, N=72, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
Enrollment closed
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
huCART19-IL18
7ms
Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure. (PubMed, N Engl J Med)
In this small study, huCART19-IL18 had a safety profile consistent with other CAR T-cell treatments and showed promising efficacy at low cell doses in patients with lymphoma after the failure of previous anti-CD19 CAR T-cell therapy. (ClinicalTrials.gov number, NCT04684563.).
Journal
|
IL18 (Interleukin 18)
|
huCART19-IL18
2years
TmCD19-IL18 in CD19+ Cancers (clinicaltrials.gov)
P1, N=24, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
Enrollment open • CAR T-Cell Therapy
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
huCART19-IL18
over2years
TmCD19-IL18 in CD19+ Cancers (clinicaltrials.gov)
P1, N=24, Not yet recruiting, University of Pennsylvania
New P1 trial • CAR T-Cell Therapy
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • IGH (Immunoglobulin Heavy Locus) • IL18 (Interleukin 18)
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
huCART19-IL18
Share via
